8-K: FDA Approves Corcept's Lifyorli for Ovarian Cancer

Corcept Therapeutics announced FDA approval of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer.

Summary

• The U.S. Food and Drug Administration (FDA) has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• Eligible patients must have received one to three prior systemic treatment regimens, with at least one including bevacizumab.
• Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA).
• The approval is based on positive outcomes from the pivotal ROSELLA trial, which enrolled 381 patients.
• Patients treated with Lifyorli plus nab-paclitaxel experienced a 35% reduction in the risk of death (hazard ratio: 0.65; p-value: 0.0004) compared to nab-paclitaxel monotherapy.
• Median overall survival (OS) for the Lifyorli combination was 16.0 months, versus 11.9 months for nab-paclitaxel alone, a difference of 4.1 months.
• The combination also resulted in a 30% reduction in the risk of disease progression (hazard ratio: 0.70; p-value: 0.008).
• The combination of Lifyorli with nab-paclitaxel was well-tolerated and manageable.
• Approximately 20,000 women with platinum-resistant disease are candidates to start a new therapy each year in the United States, with at least an equal number in Europe.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, marking a significant regulatory and commercial milestone for Corcept with a novel drug addressing a high unmet medical need.

Positives

• FDA approval of Lifyorli, the first selective glucocorticoid receptor antagonist (SGRA), for a difficult-to-treat cancer.
• Demonstrated a significant 35% reduction in the risk of death and a 4.1-month improvement in median overall survival (16.0 months vs. 11.9 months).
• Achieved a 30% reduction in the risk of disease progression.
• Lifyorli is positioned to become a new standard-of-care treatment for platinum-resistant ovarian cancer, addressing a high unmet medical need.
• The combination therapy was reported as well-tolerated and manageable.
• Significant market potential with an estimated 20,000 eligible women annually in the US and an equal number in Europe.

Negatives

• Prescribing information includes warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity.
• Most common adverse reactions (>20%) include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.
• Serious adverse reactions occurred in 35% of patients, including neutropenia (4%), pneumonia (3.2%), pleural effusion (3.2%), febrile neutropenia (2.1%), and fatigue (2.1%).
• Fatal adverse reactions occurred in 2.1% of patients, including septic shock (0.5%), cardiac arrest (0.5%), ischemic stroke (0.5%), and intestinal perforation (0.5%).
• Permanent discontinuation due to adverse reactions occurred in 9% of patients, with intestinal obstruction being the most common (>2%) at 2.6%.
• Dosage interruptions due to adverse reactions occurred in 72% of patients, primarily for neutropenia (44%), anemia (12%), and fatigue (7%).
• Contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes.
• Potential for drug interactions with strong CYP3A inducers, CYP2C8 and moderate CYP3A inducers, CYP2C8 inhibitors, CYP3A substrates, and certain CYP2C8 substrates.
• Higher incidence of grade 3-4 adverse events and dosage modification observed in geriatric patients (aged 65 years and older).
• Avoid Lifyorli in combination with nab-paclitaxel in patients with moderate or severe hepatic impairment.

Risks

• Neutropenia and severe infections, including febrile neutropenia and fatal septic shock, requiring careful monitoring and potential dose adjustments or discontinuation.
• Adrenal insufficiency, which can occur at any time and is increased in stress situations, potentially requiring supplemental glucocorticoids.
• Exacerbation of conditions treated with glucocorticoids if Lifyorli is co-administered, as it antagonizes glucocorticoid effects.
• Embryo-fetal toxicity, necessitating pregnancy status verification and effective contraception for females of reproductive potential and male patients with female partners of reproductive potential.
• Drug interactions that can decrease the effectiveness of Lifyorli and paclitaxel or increase the risk of adverse reactions from co-administered drugs.
• Increased risk of adverse events and dosage modifications in geriatric patients.
• Risks associated with moderate or severe hepatic impairment, where Lifyorli use should be avoided.
• General risks related to the company's ability to operate its business, develop other product candidates, obtain regulatory approvals, and protect its intellectual property.

Future Outlook

Lifyorli is positioned to become a new standard-of-care treatment for patients with platinum-resistant ovarian cancer, providing clinicians with a compelling option. Corcept aims to further demonstrate the potential of cortisol modulation in oncology and explore this new mode of treatment. The company is developing relacorilant for other cancers, including endometrial, cervical, pancreatic, and prostate cancers. Corcept is committed to ensuring timely patient access for Lifyorli, anticipating a significant market of approximately 20,000 eligible women annually in the United States and an equal number in Europe.

Management Comments

• "Lifyorli is positioned to become a new standard-of-care treatment, said Rob Coleman, M.D., Texas Oncology and special advisor to the president of the GOG Foundation. Having a new treatment for this advanced, recurrent disease will provide clinicians with a compelling option to help patients with this extremely difficult-to-treat cancer."
• "The FDAs approval of Lifyorli in combination with nab-paclitaxel is welcome news to all of us in the ovarian cancer community, said Sarah DeFeo, Chief Program Officer at Ovarian Cancer Research Alliance (OCRA). We are grateful to everyone who participated in the clinical trials, their families and the physicians who helped advance this urgently needed treatment option for patients with platinum-resistant ovarian cancer."
• "It is a privilege to bring forward a new treatment for patients who historically have had few options, said Joseph Belanoff, M.D., Corcepts Chief Executive Officer. We have worked for years to demonstrate the potential of cortisol modulation in oncology. Todays approval of Lifyorli is an important first step, but there is much more to explore with this new mode of treatment. We extend our deep appreciation to the patients and healthcare providers who participated in the clinical trials that made this approval possible."

Industry Context

StockSavvy.ai notes that the approval of Lifyorli represents a significant advancement in the treatment landscape for platinum-resistant ovarian cancer, a disease with limited therapeutic options and high unmet medical need. As the first FDA-approved selective glucocorticoid receptor antagonist, Lifyorli introduces a novel mechanism of action, potentially shifting treatment paradigms and offering a new standard of care. This approval could spur further research into cortisol modulation in oncology, positioning Corcept as a leader in this emerging area.

Comparison to Industry Standards

• Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA), indicating a novel mechanism of action not directly comparable to existing non-SGRA treatments for platinum-resistant ovarian cancer.
• The median overall survival benefit of 4.1 months (16.0 months vs. 11.9 months) and a 35% reduction in the risk of death in platinum-resistant ovarian cancer patients is a clinically meaningful improvement in a difficult-to-treat population.
• For context, other treatments for platinum-resistant ovarian cancer, such as bevacizumab in combination with chemotherapy, have shown varying degrees of benefit, with some studies reporting progression-free survival benefits in the range of 3-4 months, and overall survival benefits often more modest or not statistically significant in this advanced setting.
• The safety profile, while noting significant adverse reactions, is presented as "well-tolerated and manageable" in the context of advanced cancer treatment, which often involves potent therapies with considerable side effects.

Stakeholder Impact

• Shareholders: Likely positive impact due to FDA approval, potential for increased revenue and market share, and validation of Corcept's drug development pipeline.
• Patients: Provides a new, effective treatment option for platinum-resistant ovarian cancer, a disease with few alternatives, offering improved overall and progression-free survival.
• Healthcare Providers: Offers a compelling new option for treating a difficult cancer, potentially becoming a new standard of care.
• Regulatory Authorities: Successful approval demonstrates effective clinical development and regulatory navigation.

Next Steps

• Complete results from the ROSELLA trial will be presented at the Society of Gynecologic Oncology (SGO) meeting in April.
• Corcept will continue to explore cortisol modulation in oncology, with further development of relacorilant in ovarian, endometrial, cervical, pancreatic, and prostate cancers.
• The company is committed to ensuring timely patient access for Lifyorli.
• A Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for relacorilant to treat patients with platinum-resistant ovarian cancer.

Key Dates

Recommendation

The FDA approval of Lifyorli for platinum-resistant ovarian cancer is a transformative event for Corcept Therapeutics. This represents the first selective glucocorticoid receptor antagonist approved for this indication, addressing a significant unmet medical need with a novel mechanism of action. The robust clinical trial data showing a 35% reduction in the risk of death and a 4.1-month median overall survival benefit is highly compelling and positions Lifyorli as a potential new standard of care. This approval opens a substantial market opportunity, and the company's ongoing development of relacorilant in other oncology indications further enhances its long-term growth prospects. Despite the noted adverse reactions, these are generally manageable in the context of advanced cancer treatment. This milestone significantly de-risks the company's pipeline and provides a strong foundation for future revenue growth, making it a strong buy for investors.

Keywords

Corcept Therapeutics, CORT, Lifyorli, relacorilant, FDA approval, ovarian cancer, platinum-resistant, nab-paclitaxel, glucocorticoid receptor antagonist, SGRA, ROSELLA trial, oncology, cortisol modulation, pharmaceutical, biotechnology